BOSTON —
Combined results from two studies of an experimental Alzheimer’s drug suggest it might modestly slow mental decline, especially in patients with mild disease.
Taken separately, the studies missed their main goals to significantly slow the mind-robbing disease. But pooled results found 34 percent less decline in mild Alzheimer’s patients compared to those on a dummy treatment for 18 months.
Doctors say the results do not seem strong enough to win approval of the drug now. But they show researchers are on the right track by trying to clear the sticky deposits that clog patients’ brains.
The drug is being developed by Eli Lilly & Co. and is called solanezumab. Results were reported Monday at an American Neurological Association conference in Boston.
About 35 million people worldwide have dementia, and Alzheimer’s is the most common type. In the U.S., about 5 million have Alzheimer’s. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.
Solanezumab is one of three drugs in late-stage testing that seek to alter the course of Alzheimer’s. The two studies each had about 1,000 patients, about two-thirds with mild disease and one-third with moderately severe Alzheimer’s, in 16 countries. Their average age was 75.
The main measures were two tests, one reflecting language, memory and thinking and the other, ability to perform daily activities such as eating and grooming. The combined results on the mild disease patients showed a nearly 2-point difference in the roughly 90-point score on thinking abilities.
“It’s a small difference,” said Dr. Rachelle Doody of Baylor College of Medicine. She heads a nationwide research network funded by the National Institute on Aging that did an independent analysis of Lilly’s results on the studies and presented them Monday at the conference.
Still, “you slow the decline” with the drug, she said.
Independent experts agreed.
“It’s certainly not the home run we all wanted, but we’re very encouraged by these results,” said Maria Carillo, senior director of medical and scientific relations for the Alzheimer’s Association, which had no role in the research.
A Lilly official said the company will discuss next steps with the Food and Drug Administration.
The price of Lilly shares rose more than 2 percent, or $1.22, to $49.45 in heavy Monday afternoon trading while the Standard & Poor’s 500 index fell slightly. The shares set a new 52-week high price of $49.78 before retreating slightly.
Business
Alzheimer drug shows some promise in mild disease
- Business
-
-
Stock market falls as traders fear stimulus cuts
Stocks are falling after the Federal Reserve gave a slightly more optimistic outlook for the U.S. economy, which investors took as a hint that the bank was nearer to a decision to reduce its economic stimulus program.
-
Top UK court overturns sanctions on Iranian bank
Britain’s Supreme Court quashed sanctions against an Iranian bank penalized over its alleged links to Iran’s nuclear weapons program, saying Wednesday that Bank Mellat had been arbitrarily singled out.
-
Netflix to expand to Netherlands later this year
Netflix is going Dutch.
-
World Bank highlights climate-poverty link
The World Bank says it will increasingly view its efforts to help developing countries fight poverty through a “climate lens.”
-
Japan formally OKs new nuke safety requirements
Japan’s nuclear watchdog formally approved a set of new safety requirements for atomic power plants Wednesday, paving the way for the reopening of facilities shut down since the Fukushima disaster in a move critics charge is too hasty.
-
World Food Prize goes to 3 biotech scientists
The World Food Prize Foundation on Wednesday took the bold step of awarding this year’s prize to three pioneers of plant biotechnology whose work brought the world genetically modified crops.
-
Investors look for answers on economy from Fed
Worry and speculation have consumed investors since Chairman Ben Bernanke spoke to Congress last month about the Federal Reserve’s drive to keep long-term interest rates at record lows.
-
Dish won’t submit revised bid for Sprint
Satellite TV operator Dish Network Corp. said Tuesday it would not submit a revised bid for Sprint, leaving the path open for the wireless carrier to accept what it already considers a superior offer from Japan’s Softbank.
-
West Virginia mine safety lab creates disasters to train
Orange flames lick at the roof of the coal mine, heat building and visibility dropping as smoke begins to fill the underground passageway.
-
Stocks edge lower as investors wait on Fed
Stocks edged lower in early trading on Wall Street Wednesday as investors waited for word from the Federal Reserve.
- More Business Headlines
-
James Gandolfini Dies at Age 51
Fmr. TWA Flight 800 Investigators Want New Probe
Raw: Heat, Spurs Back on Court Ahead of Game 7
Dolce and Gabbana Convicted of Tax Evasion
Paris, Prince Depositions Used in Jackson Trial
Coiffed Cattle Get Their Close-up
In Berlin, Obama Channels Cold War Activism
Police at Patriots Tight End's Home for 2nd Day
Fed Suggests Bond Purchases Could Slow
AP: DOJ Broke Own Rules Seizing Phone Records
Raw: Baby White Rhino Debuts at Australian Zoo
Time Lapse: Rebuilding Bridge Post-collapse
Ohio Woman Accuses 3 of Holding Her Captive
Hunt for Ex-Teamster Boss Hoffa's Remains Ends
